SAN FRANCISCO, Nov. 3, 2017 /PRNewswire/ --áSymic Bio, a biopharmaceutical company developing novel matrix-targeting
"Dr. Froland will play an integral role at Symic as we build our capabilities for potential commercial-scale manufacturing," said Ken Horne, Symic Bio's Chief Executive Officer. "His experience with peptide biochemistry will be extremely helpful in satisfying the requirements for production of our novel category of therapeutics targeting the extracellular matrix."
"Symic Bio represents an extraordinary opportunity of bringing a novel class of therapeutics focused on the biology of the extracellular matrix to underserved areas of medical need," commented Dr. Froland. "The Symic Team has already progressed two programs into mid-stage clinical development and I am very excited to join them in accelerating the further development of these novel therapeutics through the commercialization process and into the hands of physicians and their patients."
Dr. Froland was most recently Associate Vice President at Merck & Co., Inc. where he was responsible for biopharmaceutical product development, commercialization and manufacturing strategy. He has previously worked at Calypte Biomedical, Questcor Pharmaceuticals, Bayer Pharmaceuticals and Aerovance. Dr. Froland is the co-inventor on three patents related to synthesis of therapeutic peptides and has authored 20 peer-reviewed publications in the fields of biochemistry and structural biology. He received his Ph.D. in Biochemistry from the University of Minnesota Medical School and conducted post-doctoral research at the Department of Chemistry, University of California, Berkeley.
About Symic Bio
Symic Bio is a biopharmaceutical company developing novel matrix-targeting biotherapeutics, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vein graft failure, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company's website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.
View original content:http://www.prnewswire.com/news-releases/symic-bio-appoints-wayne-froland-phd-as-executive-vice-president-of-technical-operations-300549284.html
SOURCE Symic Bio
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...View All